MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK-ERK Signaling

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Evans, Catherine ^a   Cook, Simon J ^a   Coleman, Michael P ^a   Gilley, Jonathan ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BIX 02189; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE; NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE 2; PROTEASOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME STABILITY; HUMAN; HUMAN CELL; MOUSE; NERVE FIBER; NEUROPATHOLOGY; NEUROPROTECTION; NEWBORN; NONHUMAN; PHENOTYPE; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WALLERIAN DEGENERATION;

ANIMALS; AXONS; BUTADIENES; CELL LINE; ENZYME STABILITY; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE KINASE 5; MAP KINASE SIGNALING SYSTEM; NICOTINAMIDE-NUCLEOTIDE ADENYLYLTRANSFERASE; NITRILES; PHENOTYPE; PROTEIN KINASE INHIBITORS; RATS; SUPERIOR CERVICAL GANGLION; WALLERIAN DEGENERATION;

EID: 84885032145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076505     Document Type: Article

References (39)

1. Coleman M, (2005) Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 6: 889-898.
2. Conforti L, Tarlton A, Mack TG, Mi W, Buckmaster EA, et al. (2000) A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse. Proc Natl Acad Sci U S A 97: 11377-11382.
3. Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, et al. (2001) Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 4: 1199-1206.
4. Barrientos SA, Martinez NW, Yoo S, Jara JS, Zamorano S, et al. (2011) Axonal degeneration is mediated by the mitochondrial permeability transition pore. J Neurosci 31: 966-978.
5. Bhattacharya MR, Gerdts J, Naylor SA, Royse EX, Ebstein SY, et al. (2012) A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degeneration. J Neurosci 32: 5054-5061.
6. Gilley J, Coleman MP, (2010) Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol 8: e1000300.
7. Miller BR, Press C, Daniels RW, Sasaki Y, Milbrandt J, et al. (2009) A dual leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration. Nat Neurosci 12: 387-389.
8. Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, et al. (2012) dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science 337: 481-484.
9. Shin JE, Miller BR, Babetto E, Cho Y, Sasaki Y, et al. (2012) SCG10 is a JNK target in the axonal degeneration pathway. Proc Natl Acad Sci U S A.
10. Wakatsuki S, Saitoh F, Araki T, (2011) ZNRF1 promotes Wallerian degeneration by degrading AKT to induce GSK3B-dependent CRMP2 phosphorylation. Nat Cell Biol 13: 1415-1423.
11. Xiong X, Hao Y, Sun K, Li J, Li X, et al. (2012) The Highwire ubiquitin ligase promotes Wallerian degeneration by tuning levels of Nmnat protein. PLoS Biol In Press.
12. Zhai Q, Wang J, Kim A, Liu Q, Watts R, et al. (2003) Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. Neuron 39: 217-225.
13. Babetto E, Beirowski B, Russler EV, Milbrandt J, DiAntonio A, (2013) The Phr1 ubiquitin ligase promotes injury-induced axon self-destruction. Cell Rep 3: 1422-1429.
14. Gerdts J, Sasaki Y, Vohra B, Marasa J, Milbrandt J, (2011) Image-based screening identifies novel roles for IkappaB kinase and glycogen synthase kinase 3 in axonal degeneration. J Biol Chem 286: 28011-28018.
15. Babetto E, Beirowski B, Janeckova L, Brown R, Gilley J, et al. (2010) Targeting NMNAT1 to axons and synapses transforms its neuroprotective potency in vivo. J Neurosci 30: 13291-13304.
16. Beirowski B, Babetto E, Gilley J, Mazzola F, Conforti L, et al. (2009) Non-nuclear Wld(S) determines its neuroprotective efficacy for axons and synapses in vivo. J Neurosci 29: 653-668.
17. Cohen MS, Ghosh AK, Kim HJ, Jeon NL, Jaffrey SR, (2012) Chemical genetic-mediated spatial regulation of protein expression in neurons reveals an axonal function for wld(s). Chem Biol 19: 179-187.
18. Finegan KG, Wang X, Lee EJ, Robinson AC, Tournier C, (2009) Regulation of neuronal survival by the extracellular signal-regulated protein kinase 5. Cell Death Differ 16: 674-683.
19. Hetman M, Gozdz A, (2004) Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur J Biochem 271: 2050-2055.
20. Watson FL, Heerssen HM, Bhattacharyya A, Klesse L, Lin MZ, et al. (2001) Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. Nat Neurosci 4: 981-988.
21. MacInnis BL, Campenot RB, (2005) Regulation of Wallerian degeneration and nerve growth factor withdrawal-induced pruning of axons of sympathetic neurons by the proteasome and the MEK/Erk pathway. Mol Cell Neurosci 28: 430-439.
22. Kamakura S, Moriguchi T, Nishida E, (1999) Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 274: 26563-26571.
23. Mody N, Leitch J, Armstrong C, Dixon J, Cohen P, (2001) Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 502: 21-24.
24. Gilley R, Lochhead PA, Balmanno K, Oxley D, Clark J, et al. (2012) CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL. Cell Signal 24: 170-180.
25. McCaw BJ, Chow SY, Wong ES, Tan KL, Guo H, et al. (2005) Identification and characterization of mErk5-T, a novel Erk5/Bmk1 splice variant. Gene 345: 183-190.
26. Squires MS, Nixon PM, Cook SJ, (2002) Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1. Biochem J 366: 673-680.
27. Tatake RJ, O'Neill MM, Kennedy CA, Wayne AL, Jakes S, et al. (2008) Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem Biophys Res Commun 377: 120-125.
28. Bain J, McLauchlan H, Elliott M, Cohen P, (2003) The specificities of protein kinase inhibitors: an update. Biochem J 371: 199-204.
29. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
30. Davies SP, Reddy H, Caivano M, Cohen P, (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
31. Choi K, Mollapour E, Choi JH, Shears SB, (2008) Cellular energetic status supervises the synthesis of bis-diphosphoinositol tetrakisphosphate independently of AMP-activated protein kinase. Mol Pharmacol 74: 527-536.
32. Dokladda K, Green KA, Pan DA, Hardie DG, (2005) PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway. FEBS Lett 579: 236-240.
33. Yung HW, Wyttenbach A, Tolkovsky AM, (2004) Aggravation of necrotic death of glucose-deprived cells by the MEK1 inhibitors U0126 and PD184161 through depletion of ATP. Biochem Pharmacol 68: 351-360.
34. Ikegami K, Kato S, Koike T, (2004) N-alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) suppresses neuritic degeneration caused by different experimental paradigms including in vitro Wallerian degeneration. Brain Res 1030: 81-93.
35. Avery MA, Rooney TM, Pandya JD, Wishart TM, Gillingwater TH, et al. (2012) WldS prevents axon degeneration through increased mitochondrial flux and enhanced mitochondrial Ca2+ buffering. Curr Biol 22: 596-600.
36. Yahata N, Yuasa S, Araki T, (2009) Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. J Neurosci 29: 6276-6284.
37. Griffiths EJ, Rutter GA, (2009) Mitochondrial calcium as a key regulator of mitochondrial ATP production in mammalian cells. Biochim Biophys Acta 1787: 1324-1333.
38. Kitay BM, McCormack R, Wang Y, Tsoulfas P, Zhai RG, (2013) Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLD(S)-mediated axon protection independent of axonal mitochondria. Hum Mol Genet 22: 1601-1614.
39. Sasaki Y, Vohra BP, Lund FE, Milbrandt J, (2009) Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. J Neurosci 29: 5525-5535.